Connecticut lawmakers have reversed a previous legislative decision, opting to reinstate specific limits on the tetrahydrocannabinol (THC) content in cannabis flower and concentrates. This move reestablishes existing cannabis potency regulation after an earlier proposal sought to eliminate these caps, as reported by Ganjapreneur.
Legislative Reversal on THC Caps
Last month, Connecticut’s House lawmakers approved a bill that included provisions to remove the THC caps on cannabis flower and oils. The legislation also proposed an increase in the THC limit for infused beverages sold in package stores, moving from 3 milligrams to 5 milligrams. This proposal subsequently passed the Senate with an 18-17 vote, indicating a narrow margin of support for the initial changes.
However, legislative leaders have since introduced a follow-up compromise bill designed to reestablish the potency limits for cannabis flower and concentrates. State Representative Roland Lemar (D) articulated the rationale behind this legislative adjustment, stating, "We’re trying to understand and reflect the concerns that we heard from folks who thought we were moving too quickly in that space. They were not comfortable moving forward with increased potency of cannabis flower itself and we felt that since folks are willing to engage in a number of other movements that were pro-business, that we could wait and better prove the efficacy of that in the future," as reported by CT Insider via Ganjapreneur. This statement suggests a cautious approach to market liberalization, prioritizing stakeholder comfort and the demonstration of product efficacy before further deregulation of potency.
Current and Proposed Potency Limits
Under the current regulations, which are set to be restored by the compromise legislation, the THC content in cannabis flower products is capped at 35%. For concentrates, the maximum THC content is set at 70%. These limits aim to standardize product offerings and provide a framework for consumer expectations regarding potency. Additionally, cannabis flower products that test above 30% THC are required to carry a "high potency" label, a measure intended to inform consumers about product strength.
While the caps on flower and concentrates are being reinstated, the initial proposal that passed the Senate also included an increase for infused beverages from 3 milligrams to 5 milligrams of THC. This distinction indicates a differentiated regulatory approach to various product categories within the cannabis market.
Broader Industry Modernization Efforts
Despite the decision to maintain existing cannabis potency regulation for flower and concentrates, lawmakers indicated that the overall legislative proposal aims to modernize the state’s cannabis industry. The bill encompasses several other provisions intended to update the regulatory framework and expand market opportunities.
- Infused Products Expansion: The legislation includes language to permit the sale of infused coffee and teas. This expansion into new product categories could broaden the consumer base and create new revenue streams for licensed operators, reflecting an adaptation to evolving consumer preferences.
- Medical Patient Access: A significant provision allows out-of-state cannabis patients to access licensed medical facilities within Connecticut. This measure could streamline access for individuals requiring medical cannabis while traveling, potentially increasing the patient pool for registered dispensaries and aligning Connecticut with other states that offer reciprocity for medical cannabis patients. This aspect of the bill addresses patient mobility and continuity of care.
These additional components of the bill reflect an effort to evolve the state’s cannabis market while addressing specific concerns regarding product potency. The legislative process continues to balance industry development with public health considerations, particularly concerning the concentration of active cannabinoids in consumer products. The reinstatement of THC caps on flower and concentrates underscores a regulatory preference for incremental changes in market standards.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
